Summary of Pulse Biosciences FY Conference Call (March 04, 2026) Company Overview - **Company**: Pulse Biosciences (NasdaqCM:PLSE) - **CEO**: Paul LaViolette, with over 45 years in med tech, joined Pulse Biosciences after being impressed by its technology [2][3] Key Industry Insights - **Technology Focus**: Pulse Biosciences is centered on Nanosecond Pulsed Field Ablation (NSPFA), a novel technology aimed at improving clinical outcomes in various applications, particularly in electrophysiology (EP) [4][10] - **Market Potential**: The ablation catheter market is estimated at $3 billion to $3.5 billion, growing at 15%-20% annually, with significant opportunities in treating atrial fibrillation (AFib) [27] Financial Highlights - **Cash Position**: The company ended the previous year with $80 million in cash, sufficient to fund clinical trials through 2026 and into 2027 [6] - **Quarterly Burn Rate**: Currently at approximately $15 million, expected to increase as clinical trials ramp up [7] Clinical Developments - **Atrial Fibrillation (AFib)**: AFib is the most common arrhythmia, with nearly 2 million patients diagnosed annually. The company aims to revolutionize AFib treatment with its NSPFA technology [12][13] - **Clinical Data**: Recent studies show 100% clinical success at 6 months and 96% at 12 months for patients treated with NSPFA, which is unprecedented in the field [18][19] - **Workflow Efficiency**: The NSPFA procedure can achieve full pulmonary vein isolation in as little as 5 minutes, significantly faster than current methods [14][17] Technology and Innovation - **Unique Mechanism**: NSPFA operates with pulse durations in billionths of a second, which is 1,000-fold shorter than conventional systems, leading to more efficient energy delivery and reduced thermal damage [9][10] - **Intellectual Property**: The company holds a robust patent portfolio of 250 patents, covering various aspects of NSPFA technology, creating significant barriers for competitors [11][26] Future Plans - **Clinical Trials**: The company is set to commence IDE enrollment for its EP catheter in the U.S. and is also advancing a cardiac surgery program that has received FDA Breakthrough designation [22][25] - **Expansion into Oncology**: Plans to initiate clinical studies for treating papillary thyroid microcarcinoma, showcasing the versatility of NSPFA technology [24] Additional Insights - **Regulatory Focus**: The company is investing in data, regulatory approvals, and reimbursement strategies to support market development [23] - **Investigator Enthusiasm**: Positive feedback from the electrophysiology community following recent data presentations indicates growing interest and optimism about the technology [42][43] Conclusion - **Strategic Vision**: Pulse Biosciences is positioned to lead in the NSPFA market with a strong focus on clinical evidence, regulatory advancements, and innovative technology development, aiming to significantly impact the treatment landscape for AFib and beyond [26][27]